Dual inhibition of IL-17A and IL-17F in psoriatic disease​ скачать в хорошем качестве

Dual inhibition of IL-17A and IL-17F in psoriatic disease​

During the PsOPsA Hub Steering Committee Meeting on July 16, 2025, Peter Nash, Griffith University, Queensland, AU, chaired a discussion on dual inhibition of IL-17A and IL-17F in psoriatic disease. The discussion also featured Paolo Gisondi, Ulrich Mrowietz, Yukari Okubo, and Jody Quinn. Key learnings: Treatment decisions in psoriatic disease are guided by both administrative and clinical factors. o Administratively, biosimilars are recommended as first choice due to cost constraints. If treatment fails, other classes such as IL-23 (p19) or IL-17 inhibitors may be considered. o Clinically, treatment decisions are mainly driven by disease severity. Dual IL-17A/F inhibitors are favored for patients with severe, resistant, or diffuse psoriasis, as well as in those presenting with arthralgia – even in the absence of a confirmed PsA diagnosis – compared with adalimumab and other agents. In Germany, all biologics are accessible, including bimekizumab. o IL-17 inhibitors, particularly bimekizumab and ixekizumab, are the first choice for PsA. o Bimekizumab is also preferred after failure of other biologics or other treatments, and in severe skin disease. o Candida infections, especially folliculitis, remain a concern, particularly during the first year of treatment. Management is further complicated by the need to avoid azole antifungals, such as fluconazole, due to CYP450-mediated drug–drug interactions. o Despite this, bimekizumab remains a highly effective option for skin, joint, and nail involvement. In Japan, IL-17A or IL-23 inhibitors are typically used as first-line therapy for severe skin disease, while dual IL-17A/F inhibitors are reserved for use after treatment failure. For difficult-to-manage PsA, dual inhibitors are often preferred as first-line therapy. o Real-world incidence of Candida appears to be reduced with consistent oral hygiene. Patient experience of biologics found bimekizumab to give relief from psoriatic pain, and scalp and hand psoriasis, but also suggested that treatments spaced beyond 4 weeks may be to be less effective. This independent educational activity was supported by UCB. All content was developed independently. The funder was allowed no influence on the content of this activity.